Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations

NCT01482195 is registered in ClinicalTrials.gov with King Khaled Eye Specialist Hospital as lead sponsor.

NCT NCT01482195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01482195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations
Lead sponsor
King Khaled Eye Specialist Hospital
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2011
Completion date
August 31, 2019
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinal disease, retinitis pigmentosa